Quick Answer
AYTU BIOPHARMA, INC reported Operating Income of -$7.83 million for fiscal year 2025.
AYTU BIOPHARMA, INC Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$7.83M | -392.0% |
| 2024 | -$1.59M | +90.7% |
| 2023 | -$17.07M | +84.5% |
| 2022 | -$109.91M | -86.7% |
| 2021 | -$58.87M | -178.6% |
| 2020 | -$21.13M | -25.4% |
| 2019 | -$16.85M | +14.5% |
| 2018 | -$19.70M | +2.1% |
| 2017 | -$20.13M | +7.3% |
| 2016 | -$21.70M | -184.4% |
| 2015 | -$7.63M | -20.3% |
| 2014 | -$6.35M | -12009.0% |
| 2013 | -$52.4K | +7.0% |
| 2012 | -$56.4K | +57.8% |
| 2011 | -$133.6K | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | -$1.97M | -16.2% | -31.0% |
| September 30, 2025 | -$1.50M | -61.7% | -162.1% |
| March 31, 2025 | $2.42M | +251.6% | +242.8% |
| December 31, 2024 | -$1.70M | -153.9% | -82.3% |
| September 30, 2024 | -$930.0K | -7.3% | +41.8% |
| March 31, 2024 | -$1.60M | +81.3% | -150.8% |
| December 31, 2023 | $3.15M | +145.8% | +462.9% |
| September 30, 2023 | -$867.0K | +52.0% | +89.9% |
- AYTU BIOPHARMA, INC showed a decrease of -392.0% in Operating Income compared to the prior fiscal year.
- Over the 2011–2025 period, AYTU BIOPHARMA, INC’s operating income has declined by 5757.7% (from -$133.6 thousand to -$7.83 million).
- The most recent figure is from AYTU BIOPHARMA, INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on September 23, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: